Phase II trial success for anti-MADCAM1 antibody

Many patients with ulcerative colitis are refractory towards conventional therapies, highlighting a need for treatments with novel mechanisms of action. Promising targets include cell adhesion molecules such as MADCAM1 that mediate the migration of lymphocytes into sites of inflammation in the gut. In a phase II, randomized, placebo-controlled trial, the efficacy and safety of PF-00547659 — a human monoclonal antibody to MADCAM1 — was assessed in moderate to severe ulcerative colitis. Patients (n = 357) from 105 centres in 21 countries were randomized to receive placebo or one of four doses of PF-00547659 every 4 weeks. The primary endpoint was induction of clinical and endoscopic remission by week 12. In three of the four treatment groups (7.5 mg, 22.5 mg and 75 mg), remission rates were significantly greater than placebo, with the greatest clinical effects seen with doses of 22.5 mg and 75 mg. No safety or tolerance concerns were reported


  1. 1

    Vermeire, S. et al. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)30930-3 (2017)

Download references


Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dickson, I. Phase II trial success for anti-MADCAM1 antibody. Nat Rev Gastroenterol Hepatol 14, 386 (2017). https://doi.org/10.1038/nrgastro.2017.82

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing